中國抗體(03681.HK)主要產品新藥研究申請獲批
中國抗體-B(03681.HK)公佈,集團其中一項主要產品SN1011的新藥研究申請(針對多發性硬化症)已獲中國國家藥監局批準。公司將在中國開始II期臨牀試驗,以評估SN1011在中國多發性硬化症患者中的療效及安全性,計劃今年第四季首名患者入組。
SN1011是公司的第三代可逆共價BTK抑制劑,其設計在長期治療系統性紅斑狼瘡、尋常型天皰瘡、多發性硬化症、類風溼關節炎及其他免疫性疾病方面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.